MIRA

NASDAQ 已收盘

MIRA Pharmaceuticals

0.29 USD
▼-0.08-20.99%
盘后 0.30 +2.06%
2026-11-20
市值
$12.23M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
0.26 – 1.69
成交量
570.06K
Beta
1.65
目标价
—
52W 低 0.2652W 高 1.69
价格走势

公司简介

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dem...